SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — James Madison

PatientJames Madison
Date of birth2003-03-16
IdentifiersMRN HR-EN007-SYN; SSN (made up) 000-07-2618
Document date2026-09-24
AuthorJosiah Pembroke-Achebe, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month review after completing psychotherapy. [S]

History of Present Illness

Mr. Madison returns after completing all twelve psychotherapy sessions. Since his preventive visit ten weeks ago he has had one event, during his stomach illness five weeks ago, and none since; he recognizes the warning feeling earlier and uses his grounding steps. He has taken sertraline 50 mg each morning for fifteen weeks, apart from two days missed when he was vomiting; he has no side effects now. The nurse telephone check planned two weeks after starting sertraline did not take place. His mood is steadier and he worries less; he sat the law school admission test last week with extra breaks and felt he did himself justice. He has gone back to evening civic meetings with a friend who knows the first-aid plan. He has not driven and asks when he may. He has had no thoughts of death or self-harm, and the rifle remains locked. [S]

ElementDetail
EventsOne in ten weeks, during an acute illness; none for five weeks
PsychotherapyTwelve of twelve sessions completed; relapse-prevention plan written
Sertraline50 mg for fifteen weeks; no side effects now
PHQ-9 and GAD-76 and 7
DrivingNot driving; asks when he may

Review of Systems

SystemResultFinding
ConstitutionalNegativeWeight 55.2 kg; well
GastrointestinalNegativeGastroenteritis resolved within four days
NeurologicalNegativeNo events for five weeks
PsychiatricPositiveMood steadier; some worry about results; no suicidal thoughts

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Levetiracetam 500 mg oral tablet, one tablet twice daily, started at an emergency department visit four months before intake for possible seizures, without an EEGOne tablet twice dailyOral route2025-12-02 to 2026-04-30completedS
Levetiracetam 500 mg oral tablet, taper: half a tablet (250 mg) twice daily for two weeks, then half a tablet at night for one week, then stopHalf a tablet twice daily for two weeks, then half a tablet at night for one week, then stopOral route2026-04-30 to 2026-05-21completedS
Sertraline 50 mg oral tablet, half a tablet (25 mg) each morning for one week, then one tablet (50 mg) each morningHalf a tablet each morning for one week, then one tablet each morningOral route2026-06-11activeS
Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours as needed for vomiting, for up to three daysOne tablet every 8 hours as needed for vomiting, up to three daysOral route2026-08-20 to 2026-08-23completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-09-24Body height168cmS
2026-09-24Body weight55.2kgS
2026-09-24Body mass index (BMI) [Ratio]19.6kg/m2S
2026-09-24Systolic blood pressure112mm[Hg]S
2026-09-24Diastolic blood pressure70mm[Hg]S
2026-09-24Heart rate68/minS
2026-09-24Respiratory rate14/minS
2026-09-24Body temperature36.6CelS
2026-09-24Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-09-24Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
2026-09-24Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]7{score}S

Physical Exam

Vital signs recorded on 2026-09-24; see the Vital Signs section. [S]

SystemFinding
GeneralWell, brighter
Mental statusMood "steadier than in years"; affect full; logical; no suicidal ideation

Problems

ProblemClinical statusVerificationCodeProvenance
Recurrent sudden episodes of unresponsiveness for two years, two or three a month: he 'blanks out', stops speaking, slumps or sinks to the floor with his eyes closed for two to ten minutes, and afterwards is tearful and tired, with no tongue biting, incontinence, or injury; first during a period of overwork and little sleep at college; with low mood and anxiety; unchanged on levetiracetam; under evaluation for epilepsy, functional (dissociative) seizures, syncope, and other causesresolvedconfirmed R40.4S — Synthetic presenting problem echoing his documented overwork, infirm health, and low spirits, and the later accounts of sudden attacks; superseded by the diagnosis at the second visit.
Taking an antiseizure medicine (levetiracetam) started without a confirmed diagnosis of epilepsyresolvedconfirmed Z79.899S — Synthetic medication problem for teaching about avoiding unneeded antiseizure medicines; resolved when the medicine was stopped.
Functional/dissociative seizures (psychogenic nonepileptic seizures), documented by video-EEG: two habitual events captured with eyes closed and resisting opening, fluctuating unresponsiveness, and a normal waking EEG throughout, with no ictal or postictal change; normal interictal EEG and brain MRI; epilepsy and syncope excludedactiveconfirmed F44.5S — Synthetic modern diagnosis. His infirm health, overwork, and low spirits in youth are documented (D); retrospective explanations of his later attacks, including epilepsy, are disputed (R). This record does not assert what his attacks were.
Generalized anxiety disorder: worry about his future, his health, and his studies most days for more than a year, with restlessness, poor sleep, and muscle tension (GAD-7 14 at intake)activeconfirmed F41.1S — Synthetic diagnosis made at the neuropsychiatric assessment during video-EEG monitoring.
Major depressive disorder, single episode, moderate: low mood, loss of interest, poor sleep and concentration, and a sense that he will not live long, for about eighteen months (PHQ-9 13 at intake); no suicidal ideation or intentactiveconfirmed F32.1S — Synthetic diagnosis echoing, without asserting, his documented letter expecting an early death.
Acute viral gastroenteritis with mild dehydration, a day of vomiting and diarrhea after a household outbreak; one functional seizure the evening before the visit; resolvedresolvedconfirmed A08.4S — Synthetic intercurrent illness at an unscheduled visit; it echoes, without asserting, the 'bilious' illnesses recorded in his later life (CLM-0010).

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyPHQ-9Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuationCompleted today6, down from 13 (54 percent); item 9 scored 0
SurveyPHQ-9 at least monthly during acute treatmentBaseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuationDeferredMissed: after the preventive visit, no PHQ-9 was recorded for ten weeks; the sick visit in between did not repeat it. No harm: no suicidal thoughts were reported at the sick visit, and today's score shows a response. Corrective action: a monthly PHQ-9 by the care manager, by telephone or the patient portal, between visits until remission
SurveyGAD-7With the PHQ-9 when anxiety accompanies depressionCompleted today7, down from 14
SurveySuicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9)Every visit during active treatmentCompleted todayNo suicidal thoughts, intent, plan, or behavior; rifle locked; protective factors stronger
ExaminationEvent diary: frequency, duration, triggers, warning sensations, and injuriesEvery visitCompleted todayOne event in ten weeks, during gastroenteritis; none for five weeks
Medication safetySSRI tolerability check two weeks after starting2 weeks after starting and after each dose changeDeferredMissed: the nurse telephone check planned two weeks after starting sertraline was not made. Tolerability was first reviewed at the preventive visit five weeks after the start, when he reported mild nausea in the first week that had settled. No harm: no side effects now and no suicidal thoughts at any contact. Corrective action: the care manager now books the two-week call at the visit where an antidepressant is started or changed
Medication safetyAdherence and adverse effectsEvery visit during active treatmentCompleted todayTwo doses missed during vomiting; otherwise no missed doses; no side effects
Medication safetyAntiseizure medicinesEvery visitNot indicatedNone needed; emergency card in place
ReferralCBT-informed psychotherapy for functional seizuresWeekly during the courseCompleted todayCourse completed; relapse-prevention plan written
Self-managementDrivingEvery visit until clearedCompleted todayFive weeks free of events; may resume after three months, about eight weeks from now, with the neurologist's agreement
Self-managementSleep, studies, and first-aid planEvery visitCompleted todayAbout seven hours of sleep; admission test taken with accommodations; back at civic meetings
LaboratoryLithium, anticonvulsant mood-stabilizer, or antipsychotic monitoringOnly on those drugsNot indicatedNot taking any; no bipolar features

Goal progress:

Immunizations given today: Influenza vaccine, 2026-2027 season [S]

Guideline basis: CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); Hingray C, et al. Functional/dissociative seizures: Proposal for a new diagnostic label and definition by the ILAE task force. Epilepsia 2025;66(11):4162-4182 (PMID 40884444) (2025); LaFrance WC Jr, et al. Multicenter pilot treatment trial for psychogenic nonepileptic seizures: a randomized clinical trial. JAMA Psychiatry 2014;71(9):997-1005 (PMID 24989152) (2014); Goldstein LH, et al. Cognitive behavioural therapy for adults with dissociative seizures (CODES): a pragmatic, multicentre, randomised controlled trial. Lancet Psychiatry 2020;7(6):491-505 (PMID 32445688) (2020); Tolchin B, et al. Seizures, Driver Licensure, and Medical Reporting Update: An AAN Position Statement. Neurology 2025;104(7):e213459 (PMID 40073306) (2025); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); Adult Immunization Schedule by Age (2026)

Follow-up: Review in six to eight weeks, when the three-month event-free interval is reached, for driving; monthly PHQ-9 by the care manager. [S]